Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.
In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.
The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.
- Headquartered in Madison, Wisconsin
- Specializes in cancer screening and diagnostic tests
- Flagship product: Cologuard, a noninvasive colorectal cancer screening test
- Precision oncology products: Oncotype DX and OncoExTra
- Active development of liquid biopsy tests
- Exclusive intellectual property rights protecting screening technology
For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in June 2022. Key events include:
- William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 3:40 p.m. ET in Chicago.
- Jefferies Healthcare Conference on June 8, 2022, at 1:00 p.m. ET in New York.
- Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 6:20 p.m. ET in Rancho Palos Verdes.
- Nephron Liquid Biopsy Innovation Symposium on June 21, 2022, at 11:00 a.m. ET (virtual).
Exact Sciences Corp. (NASDAQ: EXAS) announced participation in the BofA Securities Healthcare Conference in Las Vegas on May 11, 2022, at 5:00 p.m. ET. Investors can access the webcast via the investor relations section of Exact Sciences' website. The company is focused on cancer diagnostics, developing tests like Cologuard and Oncotype to support patients throughout their cancer journey. Exact Sciences aims to provide innovative solutions for cancer screening and diagnosis.
Exact Sciences Corp. (NASDAQ: EXAS) announced that its Oncotype DX Breast Recurrence Score test has received the highest rating in the American Society of Clinical Oncology (ASCO) guidelines for quality of evidence. The updated guidelines expand the test's use for early-stage breast cancer patients, especially in postmenopausal women with positive lymph nodes and premenopausal patients with node-negative disease. The RxPONDER study, published in The New England Journal of Medicine, underpins this recommendation, indicating significant data supporting tailored chemotherapy decisions.
Exact Sciences Corp. (NASDAQ: EXAS) reported a 21% increase in total revenue for Q1 2022, reaching $486.6 million, compared to $402.1 million in Q1 2021. Excluding COVID-19 testing, revenue grew 24%, driven by a 28% increase in Screening revenue to $306.5 million and an 18% rise in Precision Oncology revenue to $152.6 million. Despite this growth, the company faced a net loss of $180.9 million or $1.04 per share.
The 2022 revenue outlook is raised to $1,985-$2,032 million, bolstered by strong Screening and Precision Oncology performance.
Exact Sciences Corp. (Nasdaq: EXAS) announced its first quarter 2022 financial results release scheduled for April 26, 2022, after U.S. market close. A conference call will follow at 5 p.m. ET to discuss these results and business developments. The company, recognized for its advanced cancer diagnostic tests, continues to innovate in the area of cancer screening and diagnostics.
Investors can access the live webcast through its website, with an archive available post-event for those unable to attend.
Katie Couric has partnered with Exact Sciences (NASDAQ: EXAS) to launch a year-long campaign called 'Mission to Screen,' aiming to raise awareness about colon cancer screening. The initiative emphasizes the importance of screening for all adults aged 45 and older, especially given the rising incidence of colon cancer in younger individuals. Cologuard, Exact Sciences' FDA-approved noninvasive test, is highlighted as a key screening option. Over 44 million Americans aged 45-plus remain unscreened, despite the critical role of early detection in improving treatment outcomes.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming investor conferences. The Cowen Health Care Conference will feature a fireside chat on March 7, 2022 at 9:50 a.m. ET, while the Raymond James Institutional Investors Conference will hold a fireside chat on March 8, 2022 at 4:00 p.m. ET. Webcasts can be accessed via the investor relations section of Exact Sciences' website.
Exact Sciences focuses on advanced cancer diagnostics, including Cologuard and Oncotype tests.
Exact Sciences Corp. (Nasdaq: EXAS) reported $473.8 million in revenue for Q4 2021, a 2% increase year-over-year, while total revenue for 2021 reached $1,767.1 million. Screening revenue grew 11% to $277.7 million, and Precision Oncology revenue rose 27% to $149.0 million. However, COVID-19 testing revenue fell 52% to $47.1 million. The net loss for Q4 was $220.6 million or $1.28 per share, improving from a loss of $418.3 million in the same quarter the previous year. For 2022, the company projects revenue between $1,975 and $2,027 million.
Exact Sciences Corp. (Nasdaq: EXAS) announced plans to release its fourth quarter 2021 financial results on February 22, 2022, after U.S. market close. This will be followed by a webcast and conference call at 5 p.m. ET to discuss the results and business developments. The company, known for its cancer diagnostic tests, continues to expand its product pipeline with a focus on addressing critical cancer challenges. Investors can access the webcast live on the company's website.
Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in upcoming virtual conferences. Notable events include the SVB Leerink Global Healthcare Conference on February 18, 2022, at 1:40 p.m. ET, and the Citi Healthcare Conference on February 23, 2022, at 2:45 p.m. ET. Investors can join the webcasts via the investor relations section on Exact Sciences' website. Exact Sciences is dedicated to developing cancer screening and diagnostic tests, including the well-known Cologuard and Oncotype DX.
FAQ
What is the current stock price of Exact Sciences (EXAS)?
What is the market cap of Exact Sciences (EXAS)?
What is Exact Sciences Corp's main business?
What is Cologuard?
Where is Exact Sciences Corp headquartered?
What are Oncotype DX and OncoExTra?
Is Exact Sciences developing any new tests?
What is the significance of Exact Sciences' intellectual property?
Are Exact Sciences' products used internationally?
How does Cologuard work?
What is the purpose of Oncotype DX tests?
Where can more information about Cologuard be found?
